Detection of circulating tumor cells in patients with renal cell carcinoma by reverse transcriptase polymerase chain reaction for G250/MNCA-9: Results of a prospective trial

Urologic Oncology: Seminars and Original Investigations

Volumn 24, Issue 4 SPEC. ISS., 2006, Pages 287-293

  Ohlmann, Carsten Henning ^a,b   Özgür, Enver ^a   Schrader, Andres Jan ^b   Konrad, Lutz ^b   Hofmann, Rainer ^b   Engelmann, Udo ^a   Heidenreich, Axel ^a,b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Clinical outcome; G250; MNCA 9; Operative technique; Renal cell carcinoma; Tumor cell shedding

Indexed keywords

CARBONATE DEHYDRATASE IX; COMPLEMENTARY DNA; RNA;

ADULT; AGED; ARTICLE; BENIGN TUMOR; BLOOD SAMPLING; CANCER PATIENT; CONTROLLED STUDY; CONVALESCENCE; DISEASE COURSE; FEMALE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; INTRAOPERATIVE PERIOD; KIDNEY CARCINOMA; KIDNEY PELVIS CARCINOMA; KIDNEY TUMOR; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; OPERATION DURATION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; STATISTICAL ANALYSIS; SURGICAL APPROACH; SURGICAL DRAINAGE; SURGICAL TECHNIQUE; TRANSITIONAL CELL CARCINOMA; TUMOR CELL;

EID: 33745507174     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2005.10.004     Document Type: Article

References (22)

1. Heidenreich A. Radical retroperitoneal nephrectomy. [in German]. Aktuelle Urol 35 (2004) 65-76
2. Droller M.J. Anatomic considerations in extraperitoneal approach to radical nephrectomy. Urology 36 (1990) 118-123
3. Heidenreich A., Schrader A.J., and Varga Z. Basic science and research in renal cell carcinoma. From workbench to bedside. Curr Opin Urol 13 (2003) 457-462
4. Pastorek J., Pastorekova S., Callebaut I., et al. Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment. Oncogene 9 (1994) 2877-2888
5. Liao S.Y., Brewer C., Zavada J., et al. Identification of the MN antigen as a diagnostic biomarker of cervical intraepithelial squamous and glandular neoplasia and cervical carcinomas. Am J Pathol 145 (1994) 598-609
6. McKiernan J.M., Buttyan R., Bander N.H., et al. Expression of the tumor-associated gene MN. A potential biomarker for human renal cell carcinoma. Cancer Res 57 (1997) 2362-2365
7. Liao S.Y., Aurelio O.N., Jan K., et al. Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. Cancer Res 57 (1997) 2827-2831
8. Oosterwijk E., de Weijert M., and Van Bokhoven A. Molecular characterization of the renal cell carcinoma-associated antigen G250. Proc Am Assoc Cancer Res 37 (1996) 461
9. Sommer F., Ehsan A., Caspers H.-P., et al. Risk adjustment for evaluating the outcome of urological operative procedures. J Urol 166 (2001) 968-972
10. Lerner S.E., Hawkins C.A., Blute M.L., et al. Disease outcome in patients with low stage renal cell carcinoma treated with nephron sparing or radical surgery. 1996. J Urol 167 (2002) 884-889
11. Mickisch G.H. Principles of nephrectomy for malignant disease. BJU Int 89 (2002) 488-495
12. Sugao H., Matsuda M., Nakano E., et al. Comparison of lumbar flank approach and transperitoneal approach for radical nephrectomy. Urol Int 46 (1991) 43-45
13. Kageyama Y., Fukui I., and Goto S. Treatment results of radical nephrectomy for relatively confined small renal cell carcinoma-Translumbar versus transabdominal approach. [in Japanese]. Nippon Hinyokika Gakkai Zasshi 85 (1994) 599-603
14. Bevan P., Mala C., Kindler M., et al. Results of a phase I/II study with monoclonal antibody CG250 in combination with IFN a-2A in metastatic renal cell carcinoma patients. Proc Am Soc Clin Oncol 23 (2004) 407
15. McKiernan J.M., Buttyan R., Bander N.H., et al. The detection of renal carcinoma cells in the peripheral blood with an enhanced reverse transcriptase-polymerase chain reaction assay for MN/CA9. Cancer 86 (1999) 492-497
16. de la Taille A., Katz A., and Cao Y. Blood-based RT-PCR assays of MN/CA9 or PSMA. Clinical application in renal cancer patients. Urology 56 (2000) 393-398
17. Uemura H. Molecular detection of circulating cancer cells in patients with renal cell carcinoma. [in Japanese]. Hinyokika Kiyo 45 (1999) 571-575
18. Uemura H., Nakagawa Y., Iwai A., et al. Detection of circulating MN/CA9 positive renal cell carcinoma cells during operation. Aktuelle Urol 34 (2003) 270-272
19. National Library of Medicine. Entrez Nucleotide Database. Available at: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Nucleotide. Accessed June 6, 2005.
20. Grabmaier K., Vissers J.L., De Weijert M.C., et al. Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250. Int J Cancer 85 (2000) 865-870
21. Bui M.H., Seligson D., Han K.R., et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma. Implications for prognosis and therapy. Clin Cancer Res 9 (2003) 802-811
22. Atkins M., McDermott M., and Upton M. Carbonic anhydrase IX (CAIX) expression predicts for renal cell carcinoma (RCC) patient response and survival to IL-2 therapy. Proc Am Soc Clin Oncol 23 (2004) 383 [Abstract 4512]